Providence Capital Advisors’s Alterity Therapeutics ATHE Stock Holding History

Providence Capital Advisors’s Portfolio ATHE Stock Details ATHE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.07K	Buy	+200	New	+$870	﹤0.01%	365
2024 Q4	–	Sell	-200	Closed	-$263	–	134
2024 Q3	$263	Hold	200	–	–	﹤0.01%	345
2024 Q2	$362	Hold	200	–	–	﹤0.01%	342
2024 Q1	$414	Hold	200	–	–	﹤0.01%	330
2023 Q4	$498	Hold	200	–	–	﹤0.01%	322
2023 Q3	$496	Hold	200	–	–	﹤0.01%	335
2023 Q2	$558	Hold	200	–	–	﹤0.01%	295
2023 Q1	$555	Hold	200	–	–	﹤0.01%	292
2022 Q4	$696	Hold	200	–	–	﹤0.01%	273
2022 Q3	$1K	Hold	200	–	–	﹤0.01%	294
2022 Q2	$1K	Hold	200	–	–	﹤0.01%	271
2022 Q1	$2K	Hold	200	–	–	﹤0.01%	339
2021 Q4	$1K	Hold	200	–	–	﹤0.01%	321
2021 Q3	$3K	Buy	+200	New	+$2.78K	﹤0.01%	264

Other funds holding ATHE

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Greenleaf Trust Kalamazoo, Michigan $10.4B AUM 0.97% 1-Year Est. Return

HWM

HB Wealth Management Atlanta, Georgia $17.8B AUM 24.16% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

IWC

Integrated Wealth Concepts Waltham, Massachusetts $20.5B AUM 24.45% 1-Year Est. Return

Providence Capital Advisors's ATHE Position: Q2 2026 in Review

Providence Capital Advisors opened a new position in Alterity Therapeutics (ATHE) in Q2 2026: 200 shares worth $1.07K. The stake represents ﹤0.01% of the portfolio and ranks #365 among its holdings. This is a return to the name: Providence Capital Advisors previously reported a position in ATHE as recently as Q3 2024.

Providence Capital Advisors first reported a position in ATHE in Q3 2021 and has held it in 14 quarters since. The position peaked at $3K in Q3 2021. 21 funds tracked by Wall St. Rank hold ATHE as of Q2 2026.

Providence Capital Advisors held 200 shares of Alterity Therapeutics worth $1.07K as of Q2 2026.
Alterity Therapeutics was a new Providence Capital Advisors position in Q2 2026.
Alterity Therapeutics made up ﹤0.01% of Providence Capital Advisors's portfolio in Q2 2026, its #365 holding.
Providence Capital Advisors first reported a position in Alterity Therapeutics in Q3 2021 and has held it in 14 quarters since.
Providence Capital Advisors's Alterity Therapeutics position peaked at $3K in Q3 2021.
21 funds tracked by Wall St. Rank held Alterity Therapeutics as of Q2 2026.

Based on Providence Capital Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.